JPRN-UMIN000000603已完成2 期
Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer - Phase II study of paclitaxel plus capecitabine (XP) for metastatic breast cancer
Saitama Breast Cancer Clinical Study Group (SBCCSG)0 个研究点目标入组 50 人开始时间: 2007年2月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. severe complication 2. The brain metastasis which possesses condition 3. Past history of allergic reaction 4. Past history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate 5. which has the use history of taxane or 5' DFUR or capecitabine (but the case, after taxane is prescribed in adjuvant or neo ajuvant 6months or more has elapsed, is the register possible not in addition to 1 regimen). 6. Peripheral neuropathy >= grade 2 in prior chemotherapy 7. Pregnant or lactating women 8. Doctor's decision for exclusion
研究者
相似试验
未知
2 期
Phase II Trial of Weekly Intravenous Paclitaxel plus Three Weekly Intraperitoneal Carboplatin Administration for Suboptimally Debulked Ovarian and Primary Peritoneal Carcinoma Incorporating Pharmacogenomic Analysis.Ovarian Cancer, Peritoneal CancerJPRN-UMIN000001713Development Organization for Frontier Medical Therapeutics80
招募中
不适用
Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.Advanced Gastric CancerJPRN-UMIN000015968Tottori University35
招募中
2 期
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapyMetastatic and Recurrenced Breast CancerJPRN-UMIN000009153Toho University Omori Medical Center20
招募中
2 期
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancerJPRN-UMIN000006427Toho University Omori Medical Center40
已完成
2 期
Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)Primary breast cancerJPRN-UMIN000001205Saitama Breast Cancer Clinical Study Group (SBCCSG)63